Raymond James Financial Inc. Takes $5.75 Million Position in Stevanato Group S.p.A. (NYSE:STVN)

Raymond James Financial Inc. acquired a new stake in Stevanato Group S.p.A. (NYSE:STVN - Free Report) in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund acquired 264,084 shares of the company's stock, valued at approximately $5,754,000. Raymond James Financial Inc. owned approximately 0.09% of Stevanato Group as of its most recent filing with the Securities & Exchange Commission.

Other large investors have also recently added to or reduced their stakes in the company. Van Berkom & Associates Inc. acquired a new stake in shares of Stevanato Group in the fourth quarter valued at $39,000. US Bancorp DE raised its position in Stevanato Group by 17.9% in the 4th quarter. US Bancorp DE now owns 8,527 shares of the company's stock valued at $186,000 after purchasing an additional 1,295 shares in the last quarter. Hardy Reed LLC boosted its stake in shares of Stevanato Group by 8.2% in the 3rd quarter. Hardy Reed LLC now owns 11,077 shares of the company's stock valued at $222,000 after buying an additional 840 shares during the period. Raymond James Trust N.A. grew its position in shares of Stevanato Group by 22.6% during the third quarter. Raymond James Trust N.A. now owns 12,556 shares of the company's stock worth $251,000 after buying an additional 2,317 shares in the last quarter. Finally, Captrust Financial Advisors increased its stake in shares of Stevanato Group by 12.7% during the third quarter. Captrust Financial Advisors now owns 13,100 shares of the company's stock worth $262,000 after buying an additional 1,480 shares during the period.

Analysts Set New Price Targets

STVN has been the subject of several analyst reports. Wolfe Research started coverage on shares of Stevanato Group in a report on Friday, December 13th. They set an "outperform" rating and a $28.00 price target for the company. Bank of America increased their target price on Stevanato Group from $24.00 to $26.00 and gave the company a "buy" rating in a report on Friday, December 13th. UBS Group decreased their price target on Stevanato Group from $24.00 to $23.50 and set a "neutral" rating for the company in a report on Friday, March 7th. Morgan Stanley reiterated an "equal weight" rating and issued a $23.00 price objective (down previously from $24.00) on shares of Stevanato Group in a report on Tuesday, December 3rd. Finally, William Blair restated an "outperform" rating on shares of Stevanato Group in a research note on Friday, March 7th. Two investment analysts have rated the stock with a hold rating and five have issued a buy rating to the company. Based on data from MarketBeat, Stevanato Group currently has a consensus rating of "Moderate Buy" and a consensus price target of €25.70 ($27.93).

Stevanato Group Stock Performance

NYSE:STVN traded down €0.07 ($0.08) during mid-day trading on Friday, reaching €20.25 ($22.01). 209,138 shares of the stock were exchanged, compared to its average volume of 347,647. The company has a quick ratio of 1.21, a current ratio of 1.81 and a debt-to-equity ratio of 0.22. Stevanato Group S.p.A. has a 1 year low of €16.56 ($18.00) and a 1 year high of €32.98 ($35.85). The company has a 50 day simple moving average of €20.95 and a 200-day simple moving average of €20.59. The stock has a market capitalization of $6.13 billion, a P/E ratio of 43.09, a P/E/G ratio of 7.18 and a beta of 0.60.

Stevanato Group (NYSE:STVN - Get Free Report) last announced its earnings results on Thursday, March 6th. The company reported €0.20 ($0.22) EPS for the quarter, meeting analysts' consensus estimates of €0.20 ($0.22). Stevanato Group had a net margin of 10.47% and a return on equity of 9.86%. The business had revenue of €352.68 million for the quarter, compared to analysts' expectations of €346.26 million. Analysts anticipate that Stevanato Group S.p.A. will post 0.5 earnings per share for the current fiscal year.

Stevanato Group Profile

Stevanato Group S.p.A. engages in the design, production, and distribution of products and processes to provide integrated solutions for bio-pharma and healthcare industries in Europe, the Middle East, Africa, North America, South America, and the Asia Pacific. The company operates in two segments, Biopharmaceutical and Diagnostic Solutions; and Engineering.